Danatlas Pharmaceuticals Wins the "Deloitte China Healthcare Seed Award"
Time:2025-12-17
On December 16, 2025, the highly anticipated "Deloitte China Top 50 High-Tech Growth Companies and Rising Stars & Seeds Awards Ceremony," which has drawn global attention from the innovation and technology sector, was solemnly held in Wuxi. Beijing Danatlas Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Danatlas") stood out from numerous candidate companies thanks to its groundbreaking technological innovations in the field of precision targeted cancer therapy, strong R&D capabilities, and promising market prospects, and successfully won the "Deloitte China Pharma & Healthcare Seeds Award," becoming one of the benchmark enterprises with the greatest growth potential in the pharmaceutical and healthcare sector.
This grand event, themed “Innovation Without Boundaries, Resilient Growth,” brought together over 300 industry elites, investment heavyweights, and government representatives to jointly witness the growth momentum of China’s science and technology enterprises. The Deloitte High-Tech High-Growth Awards program is designed to recognize companies that continuously innovate and achieve rapid growth. Since companies selected for this list are typically in the early stages of development, the list is often hailed as the “cradle of great tech enterprises.” Danatlas’ recent award not only signifies high recognition of the company’s technological innovation and growth potential but also underscores the industry’s full endorsement of Danatlas’ focus on cutting-edge therapeutic areas such as “synthetic lethality and transcriptional regulation.”
About Danatlas Pharmaceuticals
Danatlas Pharmaceutics is dedicated to developing next-generation, precision-targeted oncology drugs that are "First-in-Class & Best-in-Class," offering novel treatment options for patients with advanced solid tumors. The company has established several robust new-drug technology platforms—HDDP®, TFDP®, and COEP®—and has built a pipeline matrix covering multiple key targets involved in "synthetic lethality" mechanisms such as PARG, POLQ, and WRN, as well as several "transcriptional regulation" mechanisms. Among these, two core products—DAT-2645 (a PARG inhibitor) and DAT-1604 (a POLQ inhibitor)—have both entered the clinical research stage, demonstrating excellent safety, tolerability, and promising anti-tumor efficacy signals. The company is collaborating with numerous specialized clinical institutions to actively advance its core products into Phase II clinical trials.
Relying on a robust technology R&D platform, Danatlas has established a comprehensive drug development and translation system spanning the entire chain—from target identification and drug discovery to clinical development and international collaboration. The company’s R&D center is located in Beijing, and it has set up a branch center in Boston, USA, creating a globally integrated R&D structure characterized by “China-U.S. synergy.” At the same time, the company continues to deepen its global collaborations and actively promotes the international translation of innovative achievements. With nearly 60 internationally patented inventions under its global portfolio, Danatlas has successively earned national-level high-tech enterprise status and Beijing’s specialized, refined, and innovative enterprise certification.
